Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11547843 | 0.89 | HTT (0.58) | PTGS2PTGS1HTTALDH1A1LMNA | |
| SCHEMBL265232 | 0.87 | PTGS2 (0.69) | PTGS2PTGS1ALDH1A1MAOBCYP3A4 | |
| SCHEMBL3913682 | 0.83 | HTT (0.48) | PTGS2PTGS1HTTALDH1A1LMNA | |
| SCHEMBL822784 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL10708112 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL809432 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL10396881 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL4374736 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL8941654 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1HTTALDH1A1LMNA | |
| SCHEMBL14458253 | 0.83 | ALDH1A1 (0.73) | PGRHTTALDH1A1SMN1; SMN2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4349568-A | Sulfur-substituted diphenyl ethers having antiviral activity | THE DOW CHEMICAL COMPANY (US) | 1982-09-14 | — | — | US | claimed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| EP-1001930-B1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| WO-2000044712-A1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1001930-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006361-A2 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4505929-A | Sulfur-substituted diphenyl ethers having antiviral activity | THE DOW CHEMICAL COMPANY (US) | 1985-03-19 | — | — | US | disclosed |
| US-4349568-A | Sulfur-substituted diphenyl ethers having antiviral activity | THE DOW CHEMICAL COMPANY (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | PTGS2 4381/4885PTGS1 4727/4885PGR 1543/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | PTGS2 199/4885PTGS1 60/4885PGR 2551/4885 |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | PTGS2 35/4885PTGS1 118/4885PGR 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.